Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.68 |
| ▸ | CSF1R | P07333 | 8/20 | 0.68 |
| ▸ | BRAF | P15056 | 4/20 | 0.63 |
| ▸ | ABL1 | P00519 | 7/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | BCR | P11274 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024721 | 0.97 | BRAF (0.68) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL22025362 | 0.92 | ABL1 (0.72) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL22025314 | 0.90 | ABL1 (0.72) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL21942937 | 0.87 | RET (0.67) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL22024712 | 0.86 | BRAF (0.68) | KITCSF1RBRAFABL1EGFR | |
| SCHEMBL22024729 | 0.85 | BRAF (0.68) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL22024732 | 0.84 | BRAF (0.68) | KITCSF1RBRAFABL1EGFR | |
| SCHEMBL22025548 | 0.82 | BRAF (0.68) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL22025311 | 0.82 | BRAF (0.68) | KITCSF1RBRAFABL1LYN | |
| SCHEMBL3561586 | 0.81 | KIT (0.71) | KITCSF1RBRAFABL1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | KIT 495/4885CSF1R 3197/4885BRAF 65/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | KIT 495/4885CSF1R 3197/4885BRAF 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.